Chronic Bronchitis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：64頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Chronic Bronchitis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Chronic Bronchitis - Pipeline Review, H1 2014’, provides an overview of the Chronic Bronchitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chronic Bronchitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Bronchitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Bronchitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Bronchitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Bronchitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Bronchitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Bronchitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Bronchitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Chronic Bronchitis - Pipeline Review, H1 2014’, provides an overview of the Chronic Bronchitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chronic Bronchitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Bronchitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Bronchitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Bronchitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Bronchitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Bronchitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Bronchitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Bronchitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chronic Bronchitis Overview 7
Therapeutics Development 8
Pipeline Products for Chronic Bronchitis - Overview 8
Pipeline Products for Chronic Bronchitis - Comparative Analysis 9
Chronic Bronchitis - Therapeutics under Development by Companies 10
Chronic Bronchitis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Chronic Bronchitis - Products under Development by Companies 15
Chronic Bronchitis - Companies Involved in Therapeutics Development 16
Nippon Shinyaku Co., Ltd. 16
Pharmaxis Limited 17
Yuhan Corporation 18
Bioxyne Limited 19
NanoBio Corporation 20
Invion Limited 21
Medestea Research & Production S.p.A. 22
Beech Tree Labs, Inc. 23
Theron Pharmaceuticals Inc. 24
Chronic Bronchitis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 29
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
prulifloxacin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
YHD-001 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drug For Respiratory Disease - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
HI-164OV - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Lysine Acetylsalicylate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
mannitol - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
nadolol - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Drug For Chronic Bronchitis - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
TRN-101 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Chronic Bronchitis - Recent Pipeline Updates 49
Chronic Bronchitis - Dormant Projects 56
Chronic Bronchitis - Discontinued Products 57
Chronic Bronchitis - Product Development Milestones 58
Featured News & Press Releases 58
Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 58
May 16, 2013: Sunovion Pharma To Present Clinical Data On Brovana Inhalation Solution At 2013 ATS International Conference 58
Apr 30, 2013: GSK Submits Regulatory Application For Umeclidinium Monotherapy In US 59
Jul 23, 2012: Forest Labs And Almirall Announce FDA Approval Of Tudorza Pressair For Long-Term Maintenance Treatment Of COPD 60
Mar 02, 2012: Mylan Continues To Pursue Damages And Injunction Against Sunovion's Brovana In Ongoing Litigation 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63
List of Tables
Number of Products under Development for Chronic Bronchitis, H1 2014 8
Number of Products under Development for Chronic Bronchitis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Chronic Bronchitis - Pipeline by Nippon Shinyaku Co., Ltd., H1 2014 16
Chronic Bronchitis - Pipeline by Pharmaxis Limited, H1 2014 17
Chronic Bronchitis - Pipeline by Yuhan Corporation, H1 2014 18
Chronic Bronchitis - Pipeline by Bioxyne Limited, H1 2014 19
Chronic Bronchitis - Pipeline by NanoBio Corporation, H1 2014 20
Chronic Bronchitis - Pipeline by Invion Limited, H1 2014 21
Chronic Bronchitis - Pipeline by Medestea Research & Production S.p.A., H1 2014 22
Chronic Bronchitis - Pipeline by Beech Tree Labs, Inc., H1 2014 23
Chronic Bronchitis - Pipeline by Theron Pharmaceuticals Inc., H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Stage and Target, H1 2014 28
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 33
Number of Products by Stage and Molecule Type, H1 2014 35
Chronic Bronchitis Therapeutics - Recent Pipeline Updates, H1 2014 49
Chronic Bronchitis - Dormant Projects, H1 2014 56
Chronic Bronchitis - Discontinued Products, H1 2014 57
List of Figures
Number of Products under Development for Chronic Bronchitis, H1 2014 8
Number of Products under Development for Chronic Bronchitis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Top 10 Target, H1 2014 26
Number of Products by Stage and Top 10 Target, H1 2014 27
Number of Products by Top 10 Mechanism of Action, H1 2014 29
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 30
Number of Products by Top 10 Route of Administration, H1 2014 32
Number of Products by Stage and Top 10 Route of Administration, H1 2014 33
Number of Products by Top 10 Molecule Type, H1 2014 34
Number of Products by Stage and Top 10 Molecule Type, H1 2014 35
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chronic Bronchitis Overview 7
Therapeutics Development 8
Pipeline Products for Chronic Bronchitis - Overview 8
Pipeline Products for Chronic Bronchitis - Comparative Analysis 9
Chronic Bronchitis - Therapeutics under Development by Companies 10
Chronic Bronchitis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Chronic Bronchitis - Products under Development by Companies 15
Chronic Bronchitis - Companies Involved in Therapeutics Development 16
Nippon Shinyaku Co., Ltd. 16
Pharmaxis Limited 17
Yuhan Corporation 18
Bioxyne Limited 19
NanoBio Corporation 20
Invion Limited 21
Medestea Research & Production S.p.A. 22
Beech Tree Labs, Inc. 23
Theron Pharmaceuticals Inc. 24
Chronic Bronchitis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 29
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
prulifloxacin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
YHD-001 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drug For Respiratory Disease - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
HI-164OV - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Lysine Acetylsalicylate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
mannitol - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
nadolol - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Drug For Chronic Bronchitis - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
TRN-101 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Chronic Bronchitis - Recent Pipeline Updates 49
Chronic Bronchitis - Dormant Projects 56
Chronic Bronchitis - Discontinued Products 57
Chronic Bronchitis - Product Development Milestones 58
Featured News & Press Releases 58
Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 58
May 16, 2013: Sunovion Pharma To Present Clinical Data On Brovana Inhalation Solution At 2013 ATS International Conference 58
Apr 30, 2013: GSK Submits Regulatory Application For Umeclidinium Monotherapy In US 59
Jul 23, 2012: Forest Labs And Almirall Announce FDA Approval Of Tudorza Pressair For Long-Term Maintenance Treatment Of COPD 60
Mar 02, 2012: Mylan Continues To Pursue Damages And Injunction Against Sunovion's Brovana In Ongoing Litigation 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63
List of Tables
Number of Products under Development for Chronic Bronchitis, H1 2014 8
Number of Products under Development for Chronic Bronchitis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Chronic Bronchitis - Pipeline by Nippon Shinyaku Co., Ltd., H1 2014 16
Chronic Bronchitis - Pipeline by Pharmaxis Limited, H1 2014 17
Chronic Bronchitis - Pipeline by Yuhan Corporation, H1 2014 18
Chronic Bronchitis - Pipeline by Bioxyne Limited, H1 2014 19
Chronic Bronchitis - Pipeline by NanoBio Corporation, H1 2014 20
Chronic Bronchitis - Pipeline by Invion Limited, H1 2014 21
Chronic Bronchitis - Pipeline by Medestea Research & Production S.p.A., H1 2014 22
Chronic Bronchitis - Pipeline by Beech Tree Labs, Inc., H1 2014 23
Chronic Bronchitis - Pipeline by Theron Pharmaceuticals Inc., H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Stage and Target, H1 2014 28
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 33
Number of Products by Stage and Molecule Type, H1 2014 35
Chronic Bronchitis Therapeutics - Recent Pipeline Updates, H1 2014 49
Chronic Bronchitis - Dormant Projects, H1 2014 56
Chronic Bronchitis - Discontinued Products, H1 2014 57
List of Figures
Number of Products under Development for Chronic Bronchitis, H1 2014 8
Number of Products under Development for Chronic Bronchitis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Top 10 Target, H1 2014 26
Number of Products by Stage and Top 10 Target, H1 2014 27
Number of Products by Top 10 Mechanism of Action, H1 2014 29
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 30
Number of Products by Top 10 Route of Administration, H1 2014 32
Number of Products by Stage and Top 10 Route of Administration, H1 2014 33
Number of Products by Top 10 Molecule Type, H1 2014 34
Number of Products by Stage and Top 10 Molecule Type, H1 2014 35
